Literature DB >> 8107252

Requirement of the Pr55gag precursor for incorporation of the Vpr product into human immunodeficiency virus type 1 viral particles.

C Lavallée1, X J Yao, A Ladha, H Göttlinger, W A Haseltine, E A Cohen.   

Abstract

The human immunodeficiency virus type 1 (HIV-1) particles consists of two molecules of genomic RNA as well as molecules originating from gag, pol, and env products, all synthesized as precursor proteins. The 96-amino-acid Vpr protein, the only virion-associated HIV-1 regulatory protein, is not part of the virus polyprotein precursors, and its incorporation into virus particles must occur by way of an interaction with a component normally found in virions. To investigate the mechanism of incorporation of Vpr into the HIV-1 virion, Vpr- proviral DNA constructs harboring mutations or deletions in specific virion-associated gene products were cotransfected with Vpr expressor plasmids in COS cells. Virus released from the transfected cells was tested for the presence of Vpr by immunoprecipitation with Vpr-specific antibodies. The results of these experiments show that Vpr is trans-incorporated into virions but at a lower efficiency than when Vpr is expressed from a proviral construct. The minimal viral genetic information necessary for Vpr incorporation was a deleted provirus encoding only the pr55gag polyprotein precursor. Incorporation of Vpr requires the expression but not the processing of gag products and is independent of pol and env expression. Direct interaction of Vpr with the Pr55gag precursor protein was demonstrated by coprecipitation experiments with gag product-specific antibodies. Overall, these results indicate that HIV-1 Vpr is incorporated into the nascent virion through an interaction with the Gag precursor polyprotein and demonstrate a novel mechanism by which viral protein can be incorporated into virus particles.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8107252      PMCID: PMC236654     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

Review 1.  Functions of the auxiliary gene products of the human immunodeficiency virus type 1.

Authors:  B R Cullen; W C Greene
Journal:  Virology       Date:  1990-09       Impact factor: 3.616

2.  Mutations of RNA and protein sequences involved in human immunodeficiency virus type 1 packaging result in production of noninfectious virus.

Authors:  A Aldovini; R A Young
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

3.  Human immunodeficiency virus type 1 Pr55gag and Pr160gag-pol expressed from a simian virus 40 late replacement vector are efficiently processed and assembled into viruslike particles.

Authors:  A J Smith; M I Cho; M L Hammarskjöld; D Rekosh
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

4.  Retroviral RNA packaging: sequence requirements and implications.

Authors:  M L Linial; A D Miller
Journal:  Curr Top Microbiol Immunol       Date:  1990       Impact factor: 4.291

5.  Human immunodeficiency virus vpr product is a virion-associated regulatory protein.

Authors:  E A Cohen; G Dehni; J G Sodroski; W A Haseltine
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

6.  Identification of HIV-1 vpr product and function.

Authors:  E A Cohen; E F Terwilliger; Y Jalinoos; J Proulx; J G Sodroski; W A Haseltine
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

7.  Noninfectious human immunodeficiency virus type 1 mutants deficient in genomic RNA.

Authors:  R J Gorelick; S M Nigida; J W Bess; L O Arthur; L E Henderson; A Rein
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

8.  Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants.

Authors:  E Helseth; M Kowalski; D Gabuzda; U Olshevsky; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

9.  Open reading frame vpr of simian immunodeficiency virus encodes a virion-associated protein.

Authors:  X F Yu; M Matsuda; M Essex; T H Lee
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

10.  Functional analysis of CAR, the target sequence for the Rev protein of HIV-1.

Authors:  E T Dayton; D M Powell; A I Dayton
Journal:  Science       Date:  1989-12-22       Impact factor: 47.728

View more
  59 in total

1.  Functional role of residues corresponding to helical domain II (amino acids 35 to 46) of human immunodeficiency virus type 1 Vpr.

Authors:  S P Singh; B Tomkowicz; D Lai; M Cartas; S Mahalingam; V S Kalyanaraman; R Murali; A Srinivasan
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Modulation of NKG2D-mediated cytotoxic functions of natural killer cells by viral protein R from HIV-1 primary isolates.

Authors:  Tram N Q Pham; Jonathan Richard; Francine C A Gerard; Christopher Power; Éric A Cohen
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

3.  A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles.

Authors:  Y L Lu; R P Bennett; J W Wills; R Gorelick; L Ratner
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

4.  A domain of human immunodeficiency virus type 1 Vpr containing repeated H(S/F)RIG amino acid motifs causes cell growth arrest and structural defects.

Authors:  I G Macreadie; L A Castelli; D R Hewish; A Kirkpatrick; A C Ward; A A Azad
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

5.  The p6gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles.

Authors:  E Kondo; F Mammano; E A Cohen; H G Göttlinger
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

6.  Virion-targeted viral inactivation of human immunodeficiency virus type 1 by using Vpr fusion proteins.

Authors:  G P Kobinger; A Borsetti; Z Nie; J Mercier; N Daniel; H G Göttlinger; A Cohen
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

7.  Inhibition of human and simian immunodeficiency virus protease function by targeting Vpx-protease-mutant fusion protein into viral particles.

Authors:  X Wu; H Liu; H Xiao; J A Conway; J C Kappes
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 cell cycle control: Vpr is cytostatic and mediates G2 accumulation by a mechanism which differs from DNA damage checkpoint control.

Authors:  S R Bartz; M E Rogel; M Emerman
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

9.  Vpr-induced cell cycle arrest is conserved among primate lentiviruses.

Authors:  V Planelles; J B Jowett; Q X Li; Y Xie; B Hahn; I S Chen
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

10.  Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription.

Authors:  D Braaten; E K Franke; J Luban
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.